Following a re-evaluation, the EMA has recommended Eisai and Biogen’s Alzheimer’s therapy Leqembi for a subgroup of patients.
Lake Street analyst Frank Takkinen reiterated a Buy rating on ClearPoint Neuro (CLPT – Research Report) today. The company’s shares ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback